Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01163201
Other study ID # 2009LS018
Secondary ID MT2009-030910M73
Status Withdrawn
Phase Phase 1/Phase 2
First received May 26, 2010
Last updated November 29, 2017
Start date January 2014
Est. completion date January 2015

Study information

Verified date November 2017
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a unique dose-escalation trial that will titrate doses of umbilical cord blood (UCB) Treg and CD3+ Teff cells with the goal of infusing as many CD3+ Teff cells as possible without conferring grade II-IV acute graft-versus-host disease (GVHD).

In this study, the investigators propose to add UCB Treg and UCB CD3+ Teff cells to the two TCD UCB donor units with the goal of transplanting as many CD3+ Teff cells as possible without reintroducing risk of acute GVHD. The investigators hypothesize that Treg will permit the reintroduction of CD3+ Teff cells that will provide a bridge while awaiting HSC T cell recovery long term. The co-infusion of Treg will prevent GVHD without the need for prolonged pharmacologic immunosuppression.


Description:

Based on prior studies, the first patient will start at lowest dose combination (3 x 10^6/kg of Treg and 3 x 10^6/kg of CD3+ Teff cells).

One patient will be entered at each level with a minimum of 35 days to observe the patient prior to moving to the next dose level. (1) If GVHD does not occur, a "successful step", then the CD3+ Teff cell dose will increase to the next higher level for the next patient; (2) If GVHD occurs, a "failed step", then Treg dose will increase to the next higher level for the next patient. It would take a minimum of 5 (if no GVHD) and maximum of 9 patients (if GVHD is observed at each level) to complete all Treg:CD3+ Teff cell combinations.

An additional 10 patients will be enrolled to verify that this reflects the optimal combination and evaluate its safety profile.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Only patients requiring a double umbilical cord blood (UCB) transplant are to be considered for this study.

UCB Requirements

- Three UCB units are required - one for Treg production and two for UCB transplant. The unrelated UCB donors must be 4-6/6 HLA-A, B, DRB1 matched with the recipient (HLA matching using molecular techniques: A and B to antigen level resolution and DR to allele level resolution). Suitable UCB units will be selected according to the University Of Minnesota UCB Graft Selection Algorithm.

- Suitable UCB units must be ABO matched.

Disease Criteria:

- Patients aged 18 to 55 years

- Acute Myeloid Leukemia: with morphologically persistent disease in a representative bone marrow aspirate sample with = 10% blasts after at least 1 cycles of chemotherapy (if patient refuses or is disqualified from alternative protocols), or in 3rd or higher complete remission (CR).

- Acute Lymphocytic Leukemia: with morphologically persistent disease in a representative bone marrow aspirate sample with = 10% blasts after at least 1 cycles of chemotherapy, or in 3rd or higher CR

- Chronic Myelogenous Leukemia in Blast Crisis: with =10% residual blasts in the bone marrow aspirate after at least 1 cycle of induction chemotherapy in combination with a tyrosine kinase inhibitor (TKI)

- Refractory Anemia with Excess Blasts: (= 10%) in representative bone marrow aspirate sample of blasts after 1 cycle of induction chemotherapy. If treated with hypomethylating agents, patients are eligible if blast count is = 10% after 4 cycles or evidence of stable or progressive disease after at least 2 cycles.

- Chronic Myeloproliferative Disease

- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma or Follicular Lymphoma: disease must be refractory after at least two chemotherapy regimens or is chemotherapy sensitive but has residual nodal disease of = 5 cm

- Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia: disease must be refractory after at least two chemotherapy regimens or is chemotherapy sensitive but has residual nodal disease of = 5 cm

- Large Cell Non-Hodgkin's Lymphoma: disease must be refractory after at least two chemotherapy regimens or is chemotherapy sensitive but has residual nodal disease of = 5 cm

- Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other High-Grade NHL: disease must be refractory after at least two chemotherapy regimens or is chemotherapy sensitive but has residual nodal disease of = 5 cm

- Performance Status, Age, and Organ Function

- Adequate performance status defined as a Karnofsky score = 80%

- Adequate organ function defined as:

- Renal: creatinine < 2.0 mg/dL,

- Hepatic: bilirubin, AST/ALT, ALP < 5 x upper limit of normal,

- Pulmonary function: DLCOcorr > 50% normal,

- Cardiac: left ventricular ejection fraction > 45%

- Voluntary written informed consent signed before performance of any study-related procedure not part of normal medical care

Exclusion Criteria:

- Available medically suitable HLA-identical related donor

- Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days)

- History of HIV infection

- Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy

- Prior myeloablative transplant within the last 6 months

- Extensive prior therapy including > 12 months alkylator therapy or > 6 months alkylator therapy with extensive radiation

- Patients who have received Y-90 ibritumomab (Zevalin) or I-131 tositumomab (Bexxar) as part of their salvage therapy (not eligible for myeloablative umbilical cord blood transplant)

Study Design


Related Conditions & MeSH terms

  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Anemia, Refractory, with Excess of Blasts
  • Blast Crisis
  • Burkitt Lymphoma
  • Burkitt's Lymphoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia in Blast Crisis
  • Chronic Myeloproliferative Disease
  • Follicular Lymphoma
  • Hematologic Malignancy
  • High Grade Non-Hodgkin's Lymphoma
  • Large Cell Non-Hodgkin's Lymphoma
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Lymphoblastic Lymphoma
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, B-Cell, Marginal Zone
  • Lymphoma, Follicular
  • Lymphoma, Mantle-Cell
  • Lymphoma, Non-Hodgkin
  • Lymphoplasmacytic Lymphoma
  • Mantle-Cell Lymphoma
  • Marginal Zone B-cell Lymphoma
  • Myeloproliferative Disorders
  • Neoplasms
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Prolymphocytic Lymphoma
  • Small Lymphocytic Lymphoma
  • Waldenstrom Macroglobulinemia

Intervention

Biological:
Treg cells
Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10^6/kg, 10 x 10^6/kg, 30 x 10^6/kg, 100 x 10^6/kg and 300 x 10^6/kg)
CD3+ Teff cells
Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10^6 cells/kg, 6 x 10^6 cells/kg, 9 x 10^6 cells/kg, 12 x 10^6 cells/kg, and 15 x 10^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
Drug:
Fludarabine
Given intravenously on Days -8 through -6, 25 mg/m^2 over 1 hour
Cyclophosphamide
Given intravenously on Day -7 and -6, 60 mg/kg
Radiation:
Total body irradiation
Given on Days -4 through -2, 165 cGY twice a day.
Biological:
Umbilical cord blood transplantation
Infusion given on day 0

Locations

Country Name City State
United States Masonic Cancer Center, University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Optimal Cell Dose Mixture Determine the optimal cell dose mixture of UCB T regulatory and CD3+ T effector cells without the development of grade II-IV acute GVHD Day 0
Secondary Determine incidence of infusional toxicity reaction that occurs with 48 hours of product infusion 48 hours
Secondary Incidence of neutrophil recovery Determine the incidence of neutrophil recovery (absolute neutrophil count = 500/uL) at day 42 Day 42
Secondary Incidence of double and single chimerism Determine incidence of double and single unit chimerism at various time points Day +21, Day +180, 1 Year
Secondary Incidence of Viral and Fungal Infections Determine incidence of viral and fungal infections at 1 year 1 Year
Secondary 1 Year Survival Estimate the probability of survival at 1 year 1 Year
Secondary Incidence of Grade III-IV Acute Graft-Versus-Host Disease Determine the incidence of grade III-IV acute GVHD at day 100 Day 100
Secondary Incidence of Treatment Related Death Determine the incidence of treatment related mortality (TRM) at 6 months 6 Months
Secondary Incidence of Platelet Recovery Determine the incidence of platelet recovery (platelet count = 50,000/uL) at 1 year 1 Year
Secondary Incidence of Chronic Graft-Versus-Host Disease Determine the incidence of chronic GVHD at 1 year 1 Year
Secondary Incidence of Relapse Determine the incidence of relapse at 1 year 1 Year
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2